Kaletra and Yondelis

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ritonavir may increase the blood levels of trabectedin. This can increase the risk and/or severity of side effects such as nausea, vomiting, constipation, diarrhea, liver problems, heart muscle problems (e.G., heart failure), and impaired bone marrow function resulting in low numbers of different types of blood cells. You may be more likely to develop anemia, bleeding problems, and infections because of low blood cell counts. In addition, your may have an increased risk of developing a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with trabectedin, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of trabectedin, which is primarily metabolized by the isoenzyme. In eight study patients with advanced malignancies, administration of a single 0.58 mg/m2 infusion of trabectedin following the second dose of ketoconazole (200 mg twice daily for 15 doses), a potent CYP450 3A4 inhibitor, increased the dose-normalized mean trabectedin peak plasma concentration (Cmax) and systemic exposure (AUC) by 22% and 66%, respectively, compared to infusion of a single 1.3 mg/m2 dose of trabectedin alone.

MANAGEMENT: Concomitant use of trabectedin with potent CYP450 3A4 inhibitors should generally be avoided. If a potent CYP450 3A4 inhibitor is required for short-term use (i.e., less than 14 days), it is advisable to administer the CYP450 3A4 inhibitor one week after the trabectedin infusion and discontinue it the day prior to the next infusion. Close monitoring for toxicities such as myelosuppression, rhabdomyolysis, hepatotoxicity, and cardiomyopathy is recommended during long-term coadministration, and the trabectedin dosage adjusted accordingly or treatment discontinued as necessary.

Kaletra

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: n.a.

What is Kaletra?

Yondelis

Generic Name: trabectedin

Brand name: Yondelis

Synonyms: n.a.

What is Yondelis?